MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma.

被引：0

作者：

Nastoupil, Loretta J.

Song, Yuqin

Sehn, Laurie Helen

Sarkozy, Clementine

Zinzani, Pier Luigi

Silvestre, Antonio Salar

Zhang, Jun

Huang, Sha

Wang, Julie

Delarue, Richard

Trotman, Judith

机构：

[1] MD Anderson Canc Ctr, Houston, TX USA

[2] Peking Univ Canc Hosp & Inst, Beijing, Peoples R China

[3] Univ British Columbia, Vancouver, BC, Canada

[4] Inst Curie, Paris, France

[5] Univ Bologna, Bologna, Italy

[6] Hosp del Mar, Barcelona, Spain

[7] BeiGene Shanghai Co Ltd, Shanghai, Peoples R China

[8] BeiGene USA Inc, San Mateo, CA USA

[9] BeiGene Beijing Co Ltd, Beijing, Peoples R China

[10] Univ Sydney, Concord Repatriat Gen Hosp, Sydney, NSW, Australia

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS7590

引用

页数：1

共 50 条

[21] A Phase 3 Trial Comparing Bortezomib Plus Rituximab with Rituximab Alone In Patients with Relapsed, Rituximab-Naive or -Sensitive, Follicular Lymphoma
Coiffier, Bertrand
Osmanov, Evgenii
Hong, Xiaonan
Scheliga, Adriana
Mayer, Jiri
Offner, Fritz C.
Rule, Simon A.
Teixeira, Adriana
Walewski, Jan A.
Crump, Michael
Shpilberg, Ofer
Hermann, Robert
Parasuraman, Sudha
Zhu, Eugene
Enny, Christopher
Theocharous, Panteli
van de Velde, Helgi
Elsayed, Yusri
Zinzani, Pier Luigi
BLOOD, 2010, 116 (21) : 373 - 374
[22] Real-Life Experience with Lenalidomide Plus Anti-CD20 Antibodies for the Treatment of Patients (pts) with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)
Cassanello, Giulio
Rivas-Delgado, Alfredo
De Abia, Alejandro Luna
Corona, Magdalena
Luttwak, Efrat
Okwali, Michelle
Isgor, Irem
Galera, Pallavi
Boardman, Alexander P.
Caron, Philip
David, Kevin A.
Epstein-Peterson, Zachary D.
Ghione, Paola
Hamlin, Paul A.
Lue, Jennifer Kimberly
Horwitz, Steven M.
Intlekofer, Andrew M.
Johnson, William
Kumar, Anita
Moskowitz, Alison
Noy, Ariela
Owens, Colette
Palomba, Maria Lia
Stuver, Robert
Torka, Pallawi
Vardhana, Santosha A.
Zelenetz, Andrew D.
Salles, Gilles
Falchi, Lorenzo
BLOOD, 2023, 142
[23] AUGMENT: A phase 3, randomized trial to compare efficacy and safety of lenalidomide plus rituximab versus placebo plus rituximab in patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL)
Leonard, John
Gribben, John G.
Trneny, Marek
Scheinberg, Phillip
Kilavu, Nurgul
Patturajan, Moore
Fustier, Pierre
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[24] CELESTIMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab plus lenalidomide versus rituximab plus lenalidomide in patients with relapsed or refractory follicular lymphoma who have received ≥ 1 line of systemic therapy.
Nastoupil, Loretta J.
Morschhauser, Franck
Scholz, Christian W.
Bishton, Mark
Yoon, Sung-Soo
Giri, Pratyush
Wei, Michael C.
Knapp, Andrea
Li, Chi-Chung
Bottos, Alessia
Li, Haocheng
Purev, Enkhtsetseg
Bartlett, Nancy L.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[25] Lenalidomide Plus Rituximab for Relapsed or Refractory Diffuse Large B-Cell, Follicular and Transformed Lymphoma: Final Data Analysis of a Phase 2 Trial
Wang, Yucai
Wagner-Bartak, Nicolaus
Zhou, Shouhao
Fowler, Nathan
Dela Rosa, Maria Lourdes
Zhao, Donglu
Romaguera, Jorge E.
Neelapu, Sattva S.
Hagemeister, Fredrick B.
Fanale, Michelle A.
Oki, Yasuhiro
Shah, Jatin J.
Thomoas, Sheeba K.
Hosing, Chitra M.
Zhang, Liang
Badillo, Maria
Chen, Wendy
Cai, Qingqing
Zou, Dehui
Champlin, Richard E.
Fayad, Luis E.
Lee, Hun Ju
Wang, Michael
BLOOD, 2015, 126 (23)
[26] An Externally Controlled Trial to Indirectly Compare Tazemetostat Plus Lenalidomide and Rituximab Versus Lenalidomide and Rituximab after at Least One Prior Systemic Therapy in Patients with Refractory and Relapsed Follicular Lymphoma
Nastoupil, Loretta J.
Salles, Gilles
Leonard, John P.
Morschhauser, Frank
Veazey, Kylee Jordan
Perrot, Valerie
Doban, Vitalii
Bonnet, Marion
Sosinsky, Alexandra Z.
Crowley, Aaron
Lieb, Camryn
Wang, Zhengfan
Zeldow, Bret
Harton, Joanna
Wang, Shu
Garawin, Tamer
BLOOD, 2023, 142
[27] ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma
Zinzani, Pier Luigi
Mayer, Jiri
Flowers, Christopher R.
Bijou, Fontanet
De Oliveira, Ana C.
Song, Yuqin
Zhang, Qingyuan
Merli, Michele
Bouabdallah, Krimo
Ganly, Peter
Zhang, Huilai
Johnson, Roderick
Martin Garcia-Sancho, Alejandro
Provencio Pulla, Mariano
Trneny, Marek
Yuen, Sam
Tilly, Herve
Kingsley, Edwin
Tumyan, Gayane
Assouline, Sarit E.
Auer, Rebecca
Ivanova, Elena
Kim, Pil
Huang, Sha
Delarue, Richard
Trotman, Judith
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (33) : 5107 - +
[28] Phase 2 Study of Venetoclax Plus Rituximab or Randomized Ven Plus Bendamustine plus Rituximab (BR) Versus BR in Patients with Relapsed/Refractory Follicular Lymphoma: Interim Data
Zinzani, Pier Luigi
Topp, Max S.
Yuen, Sam L. S.
Rusconi, Chiara
Fleury, Isabelle
Pro, Barbara
Gritti, Giuseppe
Crump, Michael
Hsu, Wanling
Punnoose, Elizabeth A.
Hilger, James
Mobasher, Mehrdad
Hiddermann, Wolfgang
BLOOD, 2016, 128 (22)
[29] Interim Analysis of the Randomized Phase 1b/3 Study Evaluating the Safety and Efficacy of Tazemetostat Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma
Batlevi, Connie Lee
Park, Steven I.
Nastoupil, Loretta
Phillips, Tycel
Amengual, Jennifer E.
Andorsky, David
Campbell, Philip
McKay, Pamela
Pagel, John M.
Leonard, John P.
Yang, Jay
O'Connor, Heather
Hamlett, Anthony
Adib, Deyaa
Morschhauser, Franck
BLOOD, 2021, 138
[30] HuMax-CD20, a novel fully human anti-CD20 monoclonal antibody: Results of a phase I/II trial in relapsed or refractory follicular non-Hodgkins's lymphoma.
Hagenbeek, A
Plesner, T
Johnson, P
Pedersen, L
Walewski, J
Hellmann, A
Link, B
Robak, T
Wojtukiewicz, M
Pfreundschuh, M
Kneba, M
Engert, A
Sonneveld, P
Petersen, J
Radford, J
BLOOD, 2005, 106 (11) : 270B - 270B

← 1 2 3 4 5 →